However, all methods of treatment have some disadvantages. Most drugs have some side effects, which range in severity from mild nuisance effects to major complications. Moreover, many In specific terms the thiazide diuretics have proved to be the most powerful agents having this potentiation of the cardiovascular effects of hypotensive drugs. It is perhaps worth emphasizing, to an audience mainly concerned with using these agents as diuretics in oedematous states, that their use in hypertension uncomplicated by oedema usually leads to little potassium depletion, at least as far as serum levels of potassium are concerned. The standard dose of chlorothiazide of o 5 g. twice daily has been consumed regularly by many patients in our clinic for periods of up to ten years without clinical evidence of disability attributable to hypokalaemia. A more serious defect ofthese drugs in hypertension is the high incidence of hyperuricaemia which they induce. In our series (Mathew et al., I967 ) the serum uric acid levels have risen above 7 mg./ ioO ml. in over half the patients taking thiazide diuretics regularly, and clinical gout has occurred in about IS per cent. In other series even higher incidences have been noted (Demartini et al., I962) . Although the adverse effects of hyperuricaemia on renal function and its relationship to clinical gout make this a serious drawback to the use of thiazides in the treatment of hypertension, nevertheless the efficiency with which these drugs potentiate the effects of other hypotensive drugs makes them (Jerums, Ebringer, and Doyle, I968) . After a few weeks the symptoms abated, but these patients have remained normotensive now for almost eighteen months with no treatment other than diuretics (Dawbom et al., I969). Animal studies have sub-Treatment of hypertension II5 sequently confirmed that the hypotensive effects of this drug may be prolonged. Histological studies of autonomic ganglia show heavy deposits of lipofuscin which persist after guanacline treatment and which presumably represent an end result of injury to the adrenergic terminals. Similar changes occur in human autonomic ganglia in patients treated with guanacline, but their significance in these is less easy to establish because similar changes occur with ageing. A preliminary investigation of the deliberate use of this drug to induce long-lasting sympathetic impairment is yielding promising results in a few difficult patients.
Haemodialysis
Finally, the treatment of hypertension with severe renal failure has been considerably altered by the development of haemodialysis. Renal failure is a common cause of death in malignant hypertension, and when it is present it may be very difficult to manage. In common with other groups we have found that in such patients bilateral nephrectomy may make control of blood pressure much easier, probably because most such patients in our experience have very high levels of plasma renin and angiotensin.
In summary, most patients with hypertension can be fairly easily controlled with the standard drugs available today. Most difficult patients can be treated, but the methods of treatment for this small group of patients are complex and radical.
The ease with which most patients can currently be treated must inevitably cause revaluation of the indications for treatment in hypertension. In particular, it is necessary to make a decision on whether patients with mild uncomplicated hypertension should now be treated. This decision involves making a guess at whether any long-term disadvantages of drug treatment will outweigh the probable advantages of prevention of the development of cardiovascular complications. Although evidence is incomplete, our policy now is to accept all hypertensive patients, however mild or early, for long-term control of blood pressure.
